Interventional procedure consultation document - Artificial metacarpophalangeal and interphalangeal joint replacement for end-stage arthritis
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE
Interventional Procedure Consultation Document
Artificial metacarpophalangeal and interphalangeal joint replacement for end-stage arthritis
The National Institute for Clinical Excellence is examining artificial metacarpophalangeal and interphalangeal joint replacement and will publish guidance on its safety and efficacy to the NHS in England, Wales and Scotland. The Institute's Interventional Procedures Advisory Committee has considered the available evidence and the views of Specialist Advisors, who are consultants with knowledge of the procedure. The Advisory Committee has made provisional recommendations about artificial metacarpophalangeal and interphalangeal joint replacement for end-stage arthritis.
This document summarises the procedure and sets out the provisional recommendations made by the Advisory Committee. It has been prepared for public consultation. The Advisory Committee particularly welcomes:
Note that this document is not the Institute's formal guidance on this procedure. The recommendations are provisional and may change after consultation.
For further details, see the Interventional Procedures Programme manual, which is available from the Institute's website (www.nice.org.uk/ipprogrammemanual).
Closing date for comments: 23 November 2004
Target date for publication of guidance: February 2005
Note that this document is not the Institute's guidance on this procedure. The recommendations are provisional and may change after consultation.
Current evidence on the safety and efficacy of artificial metacarpophalangeal (MCP) and interphalangeal (IP) joint replacement of the hand for end-stage arthritis appears adequate to support the use of this procedure provided that the normal arrangements are in place for consent, audit and clinical governance.
Most of the evidence was based on a single type of joint prosthesis. The range of prostheses used is continually changing and clinicians are encouraged to submit their results to the appropriate joint replacement registry for evaluation of long-term outcomes of different types of prostheses.
Arthritis of the hand joints is a common condition that deteriorates over time, although the severity of symptoms, rate of deterioration and functional effects are variable. Artificial metacarpophalangeal and interphalangeal joints are used primarily to treat the pain of severe end-stage arthritis.
Conservative treatments for arthritis of the hand include anti-inflammatory and analgesic medication, and steroid injections. Other treatments include complete joint excision without replacement (also called excision arthroplasty), native graft arthroplasties (in which the patient's own tissue, typically tendons, is interposed in the space left after joint excision) and fusion of joints (arthrodesis).
|2.2||Outline of the procedure|
A general anaesthetic is usually used and a tourniquet is applied to the affected arm to maintain a blood-free operation site. An incision is made over the diseased joint and the tendons are retracted. The joint is removed with an oscillating saw and a prosthetic joint (typically made of a silicone-based material) is inserted in its place. A splint is applied to the fingers.
Four studies reported efficacy data on a total of 125 patients and 202 joints. Pain relief was the main outcome reported. In three studies, the proportion of joints with less pain after the procedure ranged from 97% (67/69) to 100% (31/31). Two studies, including 74 joints with osteoarthritis, reported that there was no significant improvement in the range of movement, but another study reported that 71% (22/31) of joints had improved power and 81% (25/31) had improved dexterity. Two studies reported that 95% (18/19) and 87% (27/31) of patients were satisfied with the result of the surgery, after mean follow-ups of 3 years and 6 years, respectively. For more details, refer to the Sources of evidence (see Appendix).
The Specialist Advisors noted concerns regarding the long-term benefits compared with the use of arthrodesis.
A systematic review, including 70 articles (15,556 MCP and IP joint replacements), reported on complications. The most common complication was change to surrounding bones, including bone cysts, osteolysis, resorption and heterotopic bone formation, in 4% (577/15,556) of implants. Other complications included implant fracture in 2% of joints (352/15,556), implant loosening in less than 1% (114/15,556) and infection in less than 1% (86/15,556). Removal of the implant was necessary in 1% (143/15,556) of joints. The reasons for removal included implant fracture, infection, loosening, pain and synovitis. Two small case series reported that 7% (5/69) and 3% (1/31) of implants had fractured after mean follow-up periods of 3 years and 6 years, respectively. For more details, refer to the Sources of evidence (see Appendix).
The Specialist Advisors listed potential adverse effects including stiffness, loosening of the prosthesis, generation of wear debris, bone resorption, nerve injury, wound haematoma, silicone synovitis, infection and prosthesis fatigue.
|2.5.1||This procedure is primarily used to treat pain in end-stage arthritis.|
|3.1||The Institute has also issued provisional recommendations, and is currently consulting on, artificial trapeziometacarpal joints of the hand for end-stage osteoarthritis (www.nice.org.uk/ip276consultation).|
Chairman, Interventional Procedures Advisory Committee
|Appendix:||Sources of evidence|
The following document, which summarises the evidence, was considered by the Interventional Procedures Advisory Committee when making its provisional recommendations.
Interventional procedures overview of artificial metacarpophalangeal and interphalangeal joint replacement for end-stage arthritis, July 2004
Available from: www.nice.org.uk/ip003overview
This page was last updated: 29 January 2011